Top

Published in:

01-07-2017 | Clinical Study

Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas

Authors: Matthieu Peyre, Loïc Feuvret, Marc Sanson, Soledad Navarro, Anne-Laure Boch, Hugues Loiseau, Michel Kalamarides

Published in: Journal of Neuro-Oncology | Issue 3/2017

Abstract

Skull base meningiomas may present as clinically aggressive tumors despite being histologically benign. Here we describe a clinico-radiological entity of diffuse midline skull base meningiomas responsible for several neurological morbidities, including hearing and vision loss, intracranial hypertension, secondary hydrocephalus and tonsillar herniation with spinal cord compression. Surgery and radiotherapy were ineffective in stopping the clinical course of those tumors. After targeted sequencing of known mutated genes in meningiomas, we discovered TRAF7 mutations in two out of four tumors, stressing the importance of focusing the research efforts of the meningioma community in understanding the mechanisms underlying TRAF7 related meningioma tumorigenesis.

Brastianos PK, Horowitz PM, Santagata S et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285–289CrossRefPubMedPubMedCentral

Clark VE, Erson-Omay EZ, Serin A et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080CrossRefPubMedPubMedCentral

Clark VE, Harmancı AS, Bai H et al (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48:1253–1259CrossRefPubMedPubMedCentral

Reuss DE, Piro RM, Jones DT et al (2013) Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125:351–358CrossRefPubMed

Sahm F, Bissel J, Koelsche C et al (2013) AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol 126:757–762CrossRefPubMed

Luetjens G, Krauss JK, Brandis A, Nakamura M (2011) Bilateral sphenoorbital hyperostotic meningiomas with proptosis and visual impairment: a therapeutic challenge. Report of three patients and review of the literature. Clin Neurol Neurosurg 113:859–863CrossRefPubMed

Dutton JJ (1992) Optic nerve sheath meningiomas. Surv Ophthalmol 37:167–183CrossRefPubMed

Kothari NA, Kulkarni KM, Lam BL (2013) Untreated bilateral optic nerve sheath meningiomas observed for 27 years. J Neuroophthalmol 33:45–47CrossRefPubMed

Alzahrani M, Gaboury L, Saliba I (2013) A rare case of large skull base meningioma mimicking otitis media with effusion. Case Rep Med 2013:1–3CrossRef

10.

Keereweer S, Metselaar RM, Dammers R, Hardillo JAU (2011) Chronic serous otitis media as a manifestation of temporal meningioma. ORL 73:287–290CrossRefPubMed

11.

Zotti T, Vito P, Stilo R (2012) The seventh ring: exploring TRAF7 functions. J Cell Physiol 227:1280–1284CrossRefPubMed

12.

Xu L-G, Li L-Y, Shu H-B (2004) TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J Biol Chem 279:17278–17282CrossRefPubMed

13.

Bouwmeester T, Bauch A, Ruffner H et al (2004) A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat Cell Biol 6:97–105CrossRefPubMed

14.

Zotti T, Uva A, Ferravante A et al (2011) TRAF7 protein promotes Lys-29-linked polyubiquitination of IκB kinase (KKγ)/NF-κB essential modulator (NEMO) and p65/RelA protein and represses NF-κB activation. J Biol Chem 286:22924–22933CrossRefPubMedPubMedCentral

15.

Yoshida H, Jono H, Kai H, Li J-D (2005) The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7. J Biol Chem 280:41111–41121CrossRefPubMed

16.

Lee JH, Sade B, Choi E et al (2006) Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma. J Neurosurg 105:60–64CrossRefPubMed

Title: Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas
Authors: Matthieu Peyre
Loïc Feuvret
Marc Sanson
Soledad Navarro
Anne-Laure Boch
Hugues Loiseau
Michel Kalamarides
Publication date: 01-07-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2480-2

At a glance: The STEP trials

Springer Medicine

Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Rapid resolution of leptomeningeal disease with targeted therapy in a metastatic melanoma patient

A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas

Factors associated with supportive care needs in glioma patients in the neuro-oncological outpatient setting

Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma

MGMT promoter methylation status: time for a frank discussion

Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations